BERLIN (Europe) – The vaccine regulator in Germany approved live human testing of a potential COVID-19 vaccine developed by BioNTech.
The vaccine’s human trial is only the fourth worldwide of a preventive agent targeting the coronavirus. The trial will be conducted on 200 healthy people between the ages of 18 and 55 in the first stage followed by testing on further people, including those at higher coronavirus risk, in a second stage.
BioNTech was developing the vaccine candidate called BNT162 partnering with pharma giant Pfizer. Vaccine tests were also planned in the U.S., once regulatory approval for human testing had been secured there.
(Photos syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field.